Slideshow: Pharmacist’s Role in Infectious Disease Management | ASHP Midyear
Drug Topics
DECEMBER 9, 2024
Pharmacist inclusion in infectious disease care teams leads to better patient outcomes.
Mon.Dec 09, 2024
247 
STAT+: Young biotech venture firm raises $500 million for its second fund
STAT
DECEMBER 9, 2024
What happens when two computer scientists and a former stem cell researcher become friends while working their way up the venture capital corporate ladder and decide to start their own firm? Well, in Dimension’s case, they end up investing in some buzzy AI startups, counseling pharmaceutical companies, ribbing one another about expense reports, and — as of Monday — are able to raise $500 million for their second fund.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Virtual Care Provides Similar Outcomes for Patients with Diabetes | ASHP Midyear
Drug Topics
DECEMBER 9, 2024
Research also showed that the percentage of no-show appointments was slightly higher in a pre-virtual group compared to a post-virtual group.
Does drinking water lower blood pressure?
The Checkup by Singlecare
DECEMBER 9, 2024
Hypertension, or high blood pressure , affects nearly half of American adults. According to the Centers for Disease Control and Prevention (CDC) , only one in four have the condition under controland thats a problem. Why? Hypertension increases your risk of heart disease and stroke, the leading causes of death in the United States. Many factors influence blood pressure, from dietary choices and physical activity levels to how well you manage stress.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacist-Led Care Leads to Better Outcomes in ASCVD | ASHP Midyear
Drug Topics
DECEMBER 9, 2024
Patients with ASCVD experienced a more significant reduction in LDL-C.
ASHP Midyear: Nearly Half of Adults With Epilepsy Use CBD Products
Pharmacy Times
DECEMBER 9, 2024
Adults with epilepsy are underrepresented in most CBD trials, including common etiologies.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Protecting High-Risk Adults from Severe RSV: New Vaccination Recommendations and Strategies
Pharmacy Times
DECEMBER 9, 2024
Pharmacists play a key role in vaccination efforts to prevent respiratory illnesses.
How Nonstatin Therapies Can Optimize Patients’ Cardiovascular Health | ASHP Midyear
Drug Topics
DECEMBER 9, 2024
John Bucheit, PharmD, discussed lipid-lowering medications and how nonstatins can be beneficial for cardiovascular health.
ASH 2024: Circulating Tumor Cells Can Serve as Biomarker for Poor Outcomes in Multiple Myeloma
Pharmacy Times
DECEMBER 9, 2024
Luca Bertamini, MD highlights the potential clinical implications of using circulating tumor cells as a biomarker in patients with newly-diagnosed multiple myeloma.
HPV Vaccine Programming More Cost-Effective for Patients Under 26
Drug Topics
DECEMBER 9, 2024
Researchers analyzed the expansion of HPV vaccination for mid-adults defined as people 26 years or older with increased HPV risk.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
Pharmacy Times
DECEMBER 9, 2024
The phase 3 CEPHEUS trial demonstrated that adding daratumumab (DARA) to the VRd regimen significantly improves minimal residual disease negativity, progression-free survival, and overall response in transplant-ineligible or transplant deferred patients with newly diagnosed multiple myeloma, establishing a new standard of care.
Barriers to CGM Uptake Among Patients, Providers | ASHP Midyear
Drug Topics
DECEMBER 9, 2024
A discussion with Kevin Cowart, PharmD, MPH, BCACP, FCCP, BCPS, assistant professor at the University of South Florida Taneja College of Pharmacy.
Phase 3 GMMG-HD7 Trial: Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma
Pharmacy Times
DECEMBER 9, 2024
The GMMG-HD7 trial evaluated the addition of isatuximab to standard induction therapy in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation, demonstrating significantly higher rates of minimal residual disease negativity and improved progression-free survival (PFS).
Challenges in Creating a Sustainable Pharmacy Workforce in Rural Areas | ASHP Midyear
Drug Topics
DECEMBER 9, 2024
A discussion with Brittany Norton, PharmD, director of ambulatory care at Sutter Health.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
ASHP Midyear: Expert Discusses Strategies for Recruitment, Retention, and Interprofessional Collaboration for Rural Pharmacies
Pharmacy Times
DECEMBER 9, 2024
The primary challenge facing rural pharmacies include recruitment and retention of staff, the need for pharmacists to handle multiple roles and expertise, and the impact of burnout and stress.
HIV Care Creates Opportunities for Pharmacists to Expand Scope
Drug Topics
DECEMBER 9, 2024
In the most recent episode of Over the Counter, Jay Holloway, PharmD, AAHIVP, discussed advancements in HIV, especially regarding the role of pharmacists.
ASHP Midyear: Pharmacists Must Proactively Consider and Implement AI Tools
Pharmacy Times
DECEMBER 9, 2024
Although challenges and obstacles persist, artificial intelligence could help rural and smaller pharmacies close gaps in care.
SGLT2 Inhibitor Outcomes Vary When Stratified By Patient Race | ASHP Midyear
Drug Topics
DECEMBER 9, 2024
Efficacy data for dapagliflozin and empagliflozin in a group of Asian patients were evaluated.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
ASH 2024: Expert Highlights Bolstered MRD Negativity, Survival With D-VRd in Newly-Diagnosed Multiple Myeloma
Pharmacy Times
DECEMBER 9, 2024
Sonja Zweegman, MD, PhD, explains the improvements in minimum residual disease negativity found after treatment with daratumumab and the VRd regimen in patients with newly-diagnosed multiple myeloma who are transplant-ineligible.
Reprieve for Chinese biotechs as BIOSECURE Act left out of key bill
Pharmaceutical Technology
DECEMBER 9, 2024
Shares in WuXi AppTec, one of those implicated in the Chinese biotech blacklisting legislation, surged following the omission.
Researchers Identify Need for Standardized Cognition Measurements in Studies of Brain Supplements
Pharmacy Times
DECEMBER 9, 2024
Brain Health is an emerging research topic, but there is not a standard outcome measure.
Johnson & Johnson seeks first drug approval for treatment of smoldering myeloma
STAT
DECEMBER 9, 2024
This roundup of news from the ASH 2024 conference first appeared in STAT’s “ASH in 30” newsletter. To get future editions, sign up here. Welcome back, ASH followers. Here’s your rundown of Monday’s news.
Citryll gains Series B funds to develop NET-targeting antibody
Pharmaceutical Technology
DECEMBER 9, 2024
Citryll has secured an oversubscribed Series B funding round, raising 85m ($89.8m) to advance the clinical development of CIT-013.
FDA Accepts NDA for Paltusotine to Treat Adult Patients With Acromegaly
Pharmacy Times
DECEMBER 9, 2024
If approved, the treatment will be the first and only once-daily, oral selective somatostatin receptor type 2 nonpeptide agonist available for acromegaly.
Priority FDA review given to AstraZeneca’s Imfinzi sBLA for MIBC
Pharmaceutical Technology
DECEMBER 9, 2024
The US FDA has granted priority review to AstraZeneca's sBLA for Imfinzi (durvalumab) for muscle-invasive bladder cancer (MIBC) treatment.
Safety Profiles of Bispecific Antibodies for RRMM
Pharmacy Times
DECEMBER 9, 2024
Panelists discuss how bispecific antibody therapies in relapsed/refractory multiple myeloma commonly present with cytokine release syndrome (CRS), immune effector cellassociated neurotoxicity syndrome (ICANS), and increased infection risks, while talquetamab specifically exhibits distinctive adverse events including nail changes, skin reactions, and oral toxicities.
UCB presents epilepsy research at American Epilepsy Society Annual Meeting
Pharmafile
DECEMBER 9, 2024
Belgian-based biopharmaceutical company UCB has announced it will present 32 abstracts at the American Epilepsy Society (AES) Annual Meeting taking place 6-10 December 2024 in California, US covering clinical and real-world data and medical research, from its pipeline programmes. The highlights of the abstracts include data in seizures associated with Dravet syndrome and […] The post UCB presents epilepsy research at American Epilepsy Society Annual Meeting appeared first on Pharmafile.
ASHP Midyear: Expert Discusses Evolving Role of Aspirin in Cardiovascular Disease Management
Pharmacy Times
DECEMBER 9, 2024
Snehal Bhatt emphasizes the need for patient-specific risk assessment and a thoughtful approach to balancing aspirin's benefits and bleeding risks as new treatment options become available.
Daiichi Sankyo secures breakthrough designation for NSCLC treatment
Pharmaceutical Technology
DECEMBER 9, 2024
The breakthrough designation for Daiichi Sankyo comes after early pooled results from two ongoing trials finding the drug was well tolerated.
Resources and Education for Operationalizing Bispecifics
Pharmacy Times
DECEMBER 9, 2024
Panelists discuss how infrastructure including specialized staff training, updated protocols, enhanced monitoring systems, and comprehensive educational resources for health care providers is essential for institutions to successfully implement and optimize bispecific antibody therapies while ensuring patient safety and treatment efficacy.
Novo Holdings’ acquisition of Catalent gains EC approval
Pharmaceutical Technology
DECEMBER 9, 2024
Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the EC for its acquisition of Catalent.
Imfinzi receives NICE recommendation for lung cancer treatment
Pharma Times
DECEMBER 9, 2024
Trial results lead to new treatment option for lung cancer
Avastin Diary 22 – Downs but mainly Ups
NF2 BioSolutions
DECEMBER 9, 2024
[IMAGE DESCRIPTION] A festive Christmas pine tree decorated with white lights and red and gold ornaments in the Oncology ward Treatments 10 th Oct 7 th Nov 5 th Dec October Avastin was on the 10 th which happened to be World Mental Health Day. As ever with NF2 the mental health and wellbeing for our NF2 kids must be top priority. In March 2024 NIHR did a study about the impact of mental health on health-related quality of life in patients with NF2-related Schwannomatosis which you can read here
Let's personalize your content